WC
Wexford Capital Portfolio holdings
AUM
$359M
1-Year Return
31.38%
This Quarter Return
-5.09%
1 Year Return
+31.38%
3 Year Return
+167.75%
5 Year Return
–
10 Year Return
–
AUM
$1.35B
AUM Growth
+$119M
(+9.7%)
Cap. Flow
+$179M
Cap. Flow
% of AUM
13.34%
Top 10 Holdings %
Top 10 Hldgs %
65.38%
Holding
216
New
96
Increased
24
Reduced
32
Closed
47
Top Buys
| 1 |
Mammoth Energy Services
TUSK
|
+$84.9M |
| 2 |
ETP
Energy Transfer Partners, L.P.
ETP
|
+$36.3M |
| 3 |
PE
PARSLEY ENERGY INC
PE
|
+$32.1M |
| 4 |
Diamondback Energy
FANG
|
+$31.8M |
| 5 |
SPDR S&P 500 ETF Trust
SPY
|
+$17.9M |
Top Sells
| 1 |
ETP
Energy Transfer Partners L.p.
ETP
|
+$43.8M |
| 2 |
Kinder Morgan
KMI
|
+$25.2M |
| 3 |
BHI
Baker Hughes
BHI
|
+$22.6M |
| 4 |
JetBlue
JBLU
|
+$17.3M |
| 5 |
Enterprise Products Partners
EPD
|
+$15.8M |
Sector Composition
| 1 | Industrials | 40.09% |
| 2 | Energy | 25.27% |
| 3 | Consumer Discretionary | 4.88% |
| 4 | Financials | 2.66% |
| 5 | Communication Services | 2.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Alkermes
ALKS
$4.45B
| $365K | 0.03% |
+6,300
| New | +$365K |
|
|
CLVS
127
DELISTED
Clovis Oncology, Inc.
CLVS
| $365K | 0.03% |
+3,900
| New | +$365K |
|
128
Bio-Techne
TECH
$7.97B
| $364K | 0.03% |
+12,400
| New | +$364K |
|
129
Amgen
AMGN
$149B
| $362K | 0.03% |
+2,100
| New | +$362K |
|
130
Vertex Pharmaceuticals
VRTX
$101B
| $361K | 0.03% |
+2,800
| New | +$361K |
|
131
Neurocrine Biosciences
NBIX
$14.1B
| $359K | 0.03% |
+7,800
| New | +$359K |
|
132
Jazz Pharmaceuticals
JAZZ
$7.65B
| $358K | 0.03% |
+2,300
| New | +$358K |
|
133
BioMarin Pharmaceuticals
BMRN
$10.4B
| $354K | 0.03% |
+3,900
| New | +$354K |
|
134
Biogen
BIIB
$21.2B
| $353K | 0.03% |
+1,300
| New | +$353K |
|
|
ALXN
135
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $353K | 0.03% |
+2,900
| New | +$353K |
|
136
Acadia Pharmaceuticals
ACAD
$3.98B
| $351K | 0.03% |
+12,600
| New | +$351K |
|
|
CELG
137
DELISTED
Celgene Corp
CELG
| $351K | 0.03% |
+2,700
| New | +$351K |
|
|
SAGE
138
DELISTED
Sage Therapeutics
SAGE
| $350K | 0.03% |
+4,400
| New | +$350K |
|
139
Range Resources
RRC
$8.41B
| $348K | 0.03% |
15,000
-3,200
| -18% | -$74.2K |
|
|
BLUE
140
DELISTED
bluebird bio
BLUE
| $347K | 0.03% |
+255
| New | +$347K |
|
141
Illumina
ILMN
$14.6B
| $347K | 0.03% |
+2,056
| New | +$347K |
|
|
SHPG
142
DELISTED
Shire pic
SHPG
| $347K | 0.03% |
+2,100
| New | +$347K |
|
143
Regeneron Pharmaceuticals
REGN
$59.4B
| $344K | 0.03% |
+700
| New | +$344K |
|
144
Alnylam Pharmaceuticals
ALNY
$61.1B
| $343K | 0.03% |
+4,300
| New | +$343K |
|
145
GeoPark
GPRK
$325M
| $341K | 0.03% |
+45,381
| New | +$341K |
|
146
Incyte
INCY
$16.2B
| $340K | 0.03% |
+2,700
| New | +$340K |
|
|
ICPT
147
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $339K | 0.03% |
+2,800
| New | +$339K |
|
148
Park Hotels & Resorts
PK
$2.39B
| $327K | 0.02% |
12,140
-12,500
| -51% | -$337K |
|
149
Peabody Energy
BTU
$2.24B
| $325K | 0.02% |
+13,301
| New | +$325K |
|
150
Qualys
QLYS
$4.82B
| $298K | 0.02% |
+7,300
| New | +$298K |
|